现在位置 >首页 > 时讯速递
[JAMA发表论文]:早期高流量氧疗与标准氧疗对急性低氧性呼吸功能衰竭患儿住院日的影响已关闭评论
Original Investigation  Caring for the Critically Ill Patient January 17, 2023 Effect of Early High-Flow Nasal Oxygen vs Standard Oxygen Therapy on Length of Hospital Stay in Hospitalized Children With Acute Hypoxemic Respiratory Failure: The PARIS-2 Randomized Clinical Trial Donna Franklin, Franz E. Babl, Shane George, et al JAMA. 2023;329(3):224-234. doi:10.1001/jama.2022.21805 Key Points Question  Does the early use of nasa...
阅读全文
[JAMA发表论文]:出院后使用托拉塞米与呋塞米对心衰患者全因病死率的影响已关闭评论
Original Investigation  January 17, 2023 Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial Robert J. Mentz, Kevin J. Anstrom, Eric L. Eisenstein, et al JAMA. 2023;329(3):214-223. doi:10.1001/jama.2022.23924 Key Points Question  Does torsemide reduce all-cause mortality compared with furosemide in patients with heart fail...
阅读全文
[NEJM发表论文]:长效干扰素Lamda早期治疗新冠病毒感染已关闭评论
ORIGINAL ARTICLE Early Treatment with Pegylated Interferon Lambda for Covid-19 Gilmar Reis, Eduardo A.S. Moreira Silva, Daniela C. Medeiros Silva, et al N Engl J Med 2023; 388:518-528DOI: 10.1056/NEJMoa2209760 Abstract BACKGROUND The efficacy of a single dose of pegylated interferon lambda in preventing clinical events among outpatients with acute symptomatic coronavirus disease 2019 (Covid-19) is unclear. METHODS We conducted a randomized, control...
阅读全文
[Lancet Respir Med发表论文]:吡非尼酮治疗类风湿关节炎相关肺间质病的安全性、耐受性与疗效已关闭评论
ARTICLES| VOLUME 11, ISSUE 1, P87-96, JANUARY 01, 2023 Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study Joshua J Solomon, Sonye K Danoff, Felix A Woodhead, et al. Lancet Respir Med 2023; 11: 87-96 Published:September 05, 2022 DOI:https://doi.org/10.1016/S2213-2600(22)00260-0 Summary Background Inters...
阅读全文
[BMJ发表论文]:新冠病毒感染轻症一年后的长新冠预后已关闭评论
Research Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study Barak Mizrahi, Tamar Sudry, Natalie Flaks-Manov, et al BMJ 2023; 380 doi: https://doi.org/10.1136/bmj-2022-072529 (Published 11 January 2023)Cite this as: BMJ 2023;380:e072529 Abstract Objectives To determine the clinical sequelae of long covid for a year after infection in patients with mild disease and to evaluate its association with age, sex, SARS-CoV-...
阅读全文
[Lancet Respir Med发表论文]:利妥昔单抗与静脉环磷酰胺治疗结缔组织病相关肺间质病变已关闭评论
ARTICLES| VOLUME 11, ISSUE 1, P45-54, JANUARY 01, 2023 Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial Toby M Maher, Veronica A Tudor, Peter Saunders, et al. Lancet Respir Med 2023; 11: 45-54 Open Access Published: November 11, 2022 DOI:https://doi.org/10.1016/S2213-2600(22)00359-...
阅读全文
[Lancet Rheumatol发表论文]:接受免疫抑制治疗患者接种第四剂新冠病毒疫苗或混合免疫已关闭评论
ARTICLES| VOLUME 5, ISSUE 1, E36-E46, JANUARY 01, 2023 Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study Kristin H Bjørlykke, Hilde S Ørbo, Anne T Tveter, et al. Lancet Rheumatol 2023; 5: E36-E46 Published:November 16, 2022 DOI:https://doi.org/10.1016/S2665-9913(22)00330-7 Summary Background Data on response and safety of repeated vaccinations and hybrid immunity in pat...
阅读全文
[NEJM发表论文]:甲基强的松龙治疗接受心脏手术的婴儿已关闭评论
ORIGINAL ARTICLE Methylprednisolone for Heart Surgery in Infants — A Randomized, Controlled Trial Kevin D. Hill, Prince J. Kannankeril, Jeffrey P. Jacobs, et al N Engl J Med 2022; 387:2138-2149DOI: 10.1056/NEJMoa2212667 Abstract BACKGROUND Although perioperative prophylactic glucocorticoids have been used for decades, whether they improve outcomes in infants after heart surgery with cardiopulmonary bypass is unknown. METHODS We conducted a multicen...
阅读全文
[Lancet Infect Dis发表论文]:SARS-CoV-2奥密克戎变异株BA.4.6对抗体中和作用的抵抗已关闭评论
CORRESPONDENCE| VOLUME 22, ISSUE 12, P1666-1668, DECEMBER 01, 2022 Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation Qian Wang, Zhiteng Li, Jerren Ho, et al Lancet Infect Dis 2022; 22: 1666-1668 SARS-CoV-2, the causative agent of the COVID-19 pandemic, continues to evolve. A subvariant of SARS-CoV-2 omicron (B.1.1.529), known as BA.4.6, emerged in March, 2022, and it appears to be expanding its coverage even in the pr...
阅读全文
[Nature Med发表论文]:顽固性系统性红斑狼疮的抗CD19 CAR T细胞治疗已关闭评论
Article Published: 15 September 2022 Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus Andreas Mackensen, Fabian Müller, Dimitrios Mougiakakos, et al Nature Medicine volume 28, pages 2124–2132 (2022) Abstract Systemic lupus erythematosus (SLE) is a life-threatening autoimmune disease characterized by adaptive immune system activation, formation of double-stranded DNA autoantibodies and organ inflammation. Five patients with ...
阅读全文
×
腾讯微博